BACKGROUND. The role of intensive conventional dose chemotherapy in advanced low grade non-Hodgkin´s lymphomas is a matter of debate, The Gruppo Italiano per lo Studio dei Linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, ProMACE-CytaBOM, as a first-line therapy in a selected group of patients with advanced follicular non-Hodgkin´s lymphoma (Fo-NHL) who were younger than 60 years. METHODS. Thirty-nine patients were included in the study (14 males, 25 females; median age, 44 years; age range, 22-60 years). Their WF histotypes were B (9 patients), C (23 patients), and D (7 patients), All of the patients had disease in an advanced clinical stage (Stage III, 15 patients; Stage IV, 24 patients), and 9 patients had B symptoms. According to the age-adjusted international Prognostic Index (IPI), 20 patients exhibited low-intermediate risk, 14 high-intermediate risk, and 5 high risk Three of the patients were not considered evaluable because they withdrew their consent after three (one patient) and four (two patients) cycles of therapy (one of these patients was in complete remission [CR], and two were in partial remission [PR]). Of the 36 evaluable patients, 4 received IF-PT after the 6 planned cycles of therapy. RESULTS. CR was achieved in 20 patients (55.5%) and PR in 14 (38.8%), One patient (2.7%) experienced disease progression during the treatment program, Eight of the 20 patients with CR (40%) relapsed. Eight patients (22.2%) died: 6 died of disease progression, 1 died of therapy consequences, and 1 died of an unrelated cause. With a median follow-up of 49 months (range, 28-79 months), the disease free survival rate was 60%. The overall survival rate was 80% after a median follow-up of 44 months (range, 3-79 months). The IPI stratification of patients shelved a borderline statistical difference in terms of time to treatment failure and overall survival. The main hematologic toxicity was neutropenia (Grade 3 in approximately 10% of patients). One patient died of sepsis. Cotrimoxazole prophylaxis was always given. Cardiac toxicity (Grade 3) was observed in 1 patient at the end of rile planned therapy. The average relative dose intensity of the drugs was 89% of the projected dose, without the regular use of growth factors. CONCLUSIONS. This study indicates that ProMACE-CytaBOM could be a suitable regimen for adult patients with advanced Fo-NHL, allowing a good CR rate and very good disease free survival rate. However, the occurrence of severe, albeit limited, adverse effects suggests that this regimen should first be used in controlled therapeutic protocols to verify its efficacy with respect to less intensive approaches.
A pilot study on the use of the ProMACE CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma / L., Baldini; A., Guffanti; P., Gobbi; M., Colombi; Federico, Massimo; P., Avanzini; L., Cavanna; C., Pieresca; Silingardi, Vittorio; At, Maiolo. - In: CANCER. - ISSN 0008-543X. - STAMPA. - 79 (6)(1997), pp. 1234-1240.
|Data di pubblicazione:||1997|
|Titolo:||A pilot study on the use of the ProMACE CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma|
|Autore/i:||L., Baldini; A., Guffanti; P., Gobbi; M., Colombi; Federico, Massimo; P., Avanzini; L., Cavanna; C., Pieresca; Silingardi, Vittorio; At, Maiolo|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1002/(SICI)1097-0142(19970315)79:6<1234|
|Codice identificativo ISI:||WOS:A1997WM57600024|
|Codice identificativo Scopus:||2-s2.0-0030894140|
|Codice identificativo Pubmed:||9070503|
|Citazione:||A pilot study on the use of the ProMACE CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma / L., Baldini; A., Guffanti; P., Gobbi; M., Colombi; Federico, Massimo; P., Avanzini; L., Cavanna; C., Pieresca; Silingardi, Vittorio; At, Maiolo. - In: CANCER. - ISSN 0008-543X. - STAMPA. - 79 (6)(1997), pp. 1234-1240.|
|Tipologia||Articolo su rivista|
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris